Track 2: R&D Progress: The Path to New Medicines

To deal with the innovation dilemma (patent loss, pipeline drying up), big pharmaceutical corporations use innovative business models to boost R&D and innovation productivity. As a result of these challenges, major corporations have had to alter or reinvent their business models in order to maintain value creation through R&D and innovation. However, to our knowledge, there is still a dearth of understanding about the "strategic alignment" of these organizational changes, as well as how organizational members view them.

Related Societies:

    Related Conference of Track 2: R&D Progress: The Path to New Medicines

    April 16-17, 2026

    19th European Biosimilars Congress

    Rome, Italy
    April 27-28, 2026

    9th European Biopharma Congress

    Paris, Aland Islands
    May 28-29, 2026

    3rd International Conference on Pharmacognosy

    Madrid, Spain
    June 08-09, 2026

    20th World Drug Delivery Summit

    London, UK
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy
    July 27-28, 2026

    19th World Drug Delivery Summit

    Paris, France
    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 26-27, 2026

    5th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 26-27, 2026

    5th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland

    Track 2: R&D Progress: The Path to New Medicines Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in